Suzanne Ildstad, Director at Talaris Therapeutics, Inc. (TALS), sold 282,124 shares at $2.39 ($685K) on 2023-06-07, disclosed to the SEC on 2023-06-09.
Scheduled sale ($685k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.39 | 75,001 | $179K | 26.2% |
| 2 | $2.39 | 75,001 | $179K | 26.2% |
| 3 | $2.48 | 40,642 | $101K | 14.7% |
| 4 | $2.48 | 40,642 | $101K | 14.7% |
| 5 | $2.46 | 25,419 | $63K | 9.1% |
| 6 | $2.46 | 25,419 |
| $63K |
| 9.1% |
| Total | $2.43 avg | 282,124 | $685K | 100% |
| Filing → |
| TALS | SELL | 2023-06-05 | $80K | — | Filing → |
| TALS | SELL | 2023-04-25 | $35K | — | Filing → |
| TALS | SELL | 2023-04-21 | $266K | — | Filing → |